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Since the identification of cannabinoid receptors in the 1990s, a research field
has been dedicated to exploring the role of the cannabinoid system in immunity
and the inflammatory response in human tissues and animal models. Although the
cannabinoid system is present and crucial in many human tissues, studying the impact
of cannabinoids on the lungs is particularly relevant because of their contact with
exogenous cannabinoids in the context of marijuana consumption. In the past two
decades, the scientific community has gathered a large body of evidence supporting
that the activation of the cannabinoid system alleviates pain and reduces inflammation.
In the context of lung inflammation, exogenous and endogenous cannabinoids
have shown therapeutic potential because of their inhibitory effects on immune cell
recruitment and functions. On the other hand, cannabinoids were shown to be
deleterious to lung function and to impact respiratory pathogen clearance. In this review,
we present the existing data on the regulation of lung immunity and inflammation by
phytocannabinoids, synthetic cannabinoids and endocannabinoids.
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IMPACT OF CANNABIS AND ITS CONSTITUENTS ON LUNG
FUNCTIONS
Numerous countries have been considering decriminalizing and/or legalizing cannabis use. In that
regard, it has become crucial for health agencies to gain a better understanding of how cannabis
and its constituents (cannabinoids) impact humans. This article reviews the impact of cannabis
consumption on the lungs as well as the impact of the endocannabinoid system in the regulation
of lung functions, given that the most popular route of cannabis ingestion is smoking.
The impact of marijuana smoking on structural and immune cells of the lungs has been of
interest to researchers for several decades. In 1985, a histological examination of lung tissue sections
was done on known marijuana smokers who had died suddenly (Morris, 1985). The author found
macrophage infiltrates in the lungs of marijuana smokers, which were often accompanied by
fibrosis with lymphocytes in areas filled with macrophages. Considering the circumstances in which
the study was conducted, it was not possible to obtain detailed information about marijuana and
tobacco use by these individuals, making it complex to confirm that these cellular changes were
caused by marijuana alone. It is now known that cannabis induces effects on lung functions that
are not found in tobacco smokers. Although there are marked differences in the composition of
marijuana smoke versus tobacco smoke (Moir et al., 2008), studies that include groups of non-
smokers, marijuana smokers, and tobacco smokers can provide good insight into the role of
marijuana and its constituents on the structures and functions of the lungs (Owen et al., 2014).
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Many studies have described lung damage in marijuana
smokers, as well as cellular damages in cells exposed to marijuana
smoke or cannabinoids in cellulo. Gong et al. (1987) performed
bronchial biopsies on volunteers and found airway hyperemia
in both marijuana- and tobacco-smoking groups, as opposed to
non-smokers. The authors also observed hyperplasia of goblet
and basal cells in both marijuana and tobacco smokers, with
a tendency toward higher hyperplasia in marijuana smokers.
Of note, cellular disorganization was present in over 50% of
marijuana smokers, but was not found in tobacco smokers.
However, this type of experimental design still does not provide
defined conditions in terms of exposure to cannabis and/or
tobacco. In this respect, a study was performed on primates
that were exposed to a low or high dose of marijuana, placebo
cigarettes or sham smoke (Fligiel et al., 1991). Cannabis exposures
were defined as two marijuana cigarettes per week for the
low-dose group, and seven marijuana cigarettes per week for
the high-dose group. Epithelial hyperplasia was found in all
groups, but there was a greater incidence and severity of
bronchiolitis, alveolar cell hyperplasia with atypia and fibrosis
in marijuana smokers. These findings indicate that cannabis
induces some types of cellular damage to the lungs that are
not observed with tobacco smoke. Therefore, some bioactive
constituents of marijuana (cannabinoids) might be responsible
for these effects, suggesting that the endocannabinoid system
could also play a role in the regulation of pulmonary health and
diseases.
The Cannabinoid Receptors and the
Lungs
The endocannabinoid system comprises cannabinoid receptors
(CB1 and CB2), their endogenous ligands (endocannabinoids)
and the enzymes involved in their metabolism. Some
cannabinoids, such as (–)-trans- 19-tetrahydrocannabinol
(19-THC), can activate the cannabinoid receptors (Felder
et al., 1995). Others, such as cannabinol and cannabidiol,
modulate cell functions through other means (Russo
et al., 2005; Kathmann et al., 2006; Ryberg et al., 2007).
The two best characterized endocannabinoids, namely 2-
arachidonoyl-glycerol (2-AG) and arachidonylethanolamide
(AEA) also activate cannabinoid receptors. In addition,
endocannabinoids activate additional receptors and can
be metabolized into other bioactive compounds that can
modulate cell functions (Turcotte et al., 2015). In the lungs, the
cannabinoid receptors were found on structural cells and most
leukocytes.
A study of the distribution of cannabinoid receptors
among human organs found both CB1 and CB2 mRNA
in the lungs and the bronchial tissue, with CB1 mRNA
levels being significantly higher than those of CB2 (Galiegue
et al., 1995; Papadaki, 2013). To this date, there has been
no report of the expression of these receptors in primary
airway epithelial cells specifically, although the mRNA and
protein for both receptors were detected in the 16HBE14o−
cell line (Gkoumassi et al., 2007). Given that airway epithelial
cells actively participate in the recognition of pathogens
as well as the recruitment of leukocytes in inflammatory
conditions (Weitnauer et al., 2016), their ability to respond
to cannabinoids and endocannabinoids should be further
investigated. To our knowledge, there has not been any report
of the expression of cannabinoid receptors by human lung
fibroblasts.
Among immune cells residing in the airways, alveolar
macrophages (AMs) are by far the most numerous, constituting
over 90% of the cells recovered by bronchoalveolar lavage
(Hunninghake et al., 1979). A recent study was performed on
human lung-resident macrophages that were isolated from the
lung tissue of patients with adenocarcinoma (Staiano et al., 2016).
CB1 and CB2 mRNA and proteins were detected in both tumor-
associated and non-tumor macrophages. CB2 levels were higher
than those of CB1, a pattern that the authors also observed in
monocyte-derived macrophages. Interestingly, the cannabinoid
receptors expressed in lung macrophages were functional
in contrast to those of monocyte-derived macrophages, as
assessed by extracellular signal-regulated kinases 1/2 (ERK1/2)
phosphorylation assays. This emphasizes the difference between
tissue-resident and blood-derived macrophages, as well as the
importance of tissue-derived factors in the modulation of
macrophage functions. Although they are the most numerous in
alveoli, other leukocytes involved in lung immunity also express
cannabinoid receptors. Human monocyte-derived dendritic
cells (DCs) express both the CB1 and CB2 receptors, and
they also have the ability to synthesize AEA and 2-AG
(Matias et al., 2002). Both CB receptors were also found in
murine bone marrow-derived DCs (Do et al., 2004; Lu et al.,
2006b).
The presence of cannabinoid receptors on circulating
leukocytes can also impact lung immunity, as many of these
cells are recruited to the lungs at different stages of the
inflammatory response. Eosinophils, for example, express large
amounts of CB2 receptors (Oka et al., 2004; Chouinard et al.,
2011, 2013). Monocytes express both cannabinoid receptors,
with a predominant expression of CB2 (Galiegue et al., 1995;
Montecucco et al., 2008; Han et al., 2009; Castaneda et al.,
2013). It is less clear whether or not neutrophils express CB2,
since discrepancies regarding its expression have been reported
(Galiegue et al., 1995; Kurihara et al., 2006; Chouinard et al.,
2013). A more detailed summary of cannabinoid receptor
expression by human leukocytes has recently been reviewed
(Turcotte et al., 2015). The role of cannabinoid receptors in
modulating the effector functions of these leukocytes is discussed
in the next sections.
Impact of Cannabis and Cannabinoids
on Structural and Inflammatory Cells
Found in the Lungs
A limited number of studies investigated the impact of
cannabinoids on structural cells found in the lungs. However,
19-THC changes the expression pattern of numerous genes
in primary human airway epithelial cells, notably PTGS2 and
IL1A, which encode cyclooxygenase-2 and the proinflammatory
cytokine interleukin (IL)-1α, respectively. Moreover, it causes a
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decrease in cell viability and mitochondrial membrane potential
in these cells (Sarafian et al., 2005). 19-THC also caused
mitochondrial damage in the lung epithelial cell line A549
(Sarafian et al., 2003). The use of A549 cells overexpressing
the CB2 receptor indicated that some of the effects of 19-
THC on the airway epithelium are CB2-dependent (Sarafian
et al., 2008). As for lung fibroblasts, early in vitro studies
reported that cannabinoids can stimulate them to synthesize
prostaglandin E2 (Burstein et al., 1983, 1986). However, these
experiments were performed in the WI-38 cell line and the
involvement of cannabinoid receptors was not elucidated, since
these studies were published before they were cloned. To our
knowledge, these findings have not been confirmed in primary
lung fibroblasts, and the involvement of CB receptors has yet to
be determined.
The first line of defense in the lungs against aerosolized
bacteria, viruses and toxins consists of resident cells such as
bronchial epithelial cells, AMs and DCs. When they encounter
a pathogen, they are able recognize it through receptors binding
specific molecular motifs found on microorganisms. This triggers
signaling events leading to the transcription of pro-inflammatory
genes and the release of mediators that induce the recruitment of
leukocytes from the circulation. In response to these chemotactic
factors, neutrophils are the first cells to be recruited to the
lungs. They exert key effector functions and thus, participate
in pathogen elimination. Lung homeostasis is restored with the
help of AMs that have acquired a pro-resolution, wound-healing
phenotype.
Numerous in cellulo studies assessed the impact of
cannabinoids on human and murine macrophage functions.
Experiments performed with mouse peritoneal macrophages
demonstrated that 19-THC downregulates NO (nitric oxide)
production in these cells, as well as tumor necrosis factor
(TNF)-α maturation and secretion (Coffey et al., 1996; Zheng
and Specter, 1996). In RAW264.7 macrophages, the impact of
19-THC on lipopolysaccharide (LPS)-induced NO production
was shown to be a consequence of NF-κB inhibition (Jeon et al.,
1996). The impact of 19-THC was also investigated in the
P388D1 cell line and was shown to impair phagocytic activity of
these murine macrophages (Tang et al., 1992).
In light of these findings, some have studied the functions
of human AMs isolated from healthy volunteers and marijuana
smokers and these reports are consistent with the data obtained
from murine macrophages. AMs from marijuana smokers were
found to have a decreased capability to ingest/kill Staphylococcus
aureus (Baldwin et al., 1997) and produced less NO following
LPS stimulation (Shay et al., 2003). This was not the case in AMs
recovered from tobacco smokers, indicating that these effects
were unlikely to be caused by the smoke itself. The incubation
of these AMs with GM-CSF or interferon (IFN)-γ restored their
ability to produce NO, suggesting that marijuana exposure causes
a decrease in cytokine priming that weakens host defense (Roth
et al., 2004).
Macrophages and DCs are highly potent antigen presenting
cells (Kopf et al., 2015). DCs constitute a crucial bridge between
innate and adaptative immunity. The immature, lung-resident
DCs that are located close to the epithelial surface of the
respiratory tract can capture and process antigens that enter the
lungs. They subsequently migrate to the lymph nodes, where they
present the antigen to naïve T cells. Given that they both express
cannabinoid receptors, AMs and DCs can respond to exogenous
cannabinoids or endocannabinoids, thereby modulating immune
responses. In murine cells, 19-THC was shown to impair LPS-
induced bone marrow-derived DC maturation (Karmaus et al.,
2013a). Moreover, treatment of these DCs with 19-THC before
cultivating them with CD8+ cells reduced their ability to produce
IFN-γ, an effect that was dependent on cannabinoid receptors.
The CB2 receptor was later implicated in the modulation of
DC functions, in a study showing that CB2 receptor agonists
decreased DC migration by reducing matrix metalloproteinase
(MMP)-9 production (Adhikary et al., 2012). This cannabinoid-
induced decrease in DC migration occurred both in vivo
and in vitro. In Legionella pneumophila-infected DCs, 19-
THC treatment impairs Th1 cytokine production, in addition
to downregulating the expression of costimulatory molecules
as well as major histocompatibility complex II (Lu et al.,
2006a). This effect was later found to involve both cannabinoid
receptors (Lu et al., 2006b). Altogether, these studies point to
a detrimental effect of cannabinoids, particularly 19-THC, on
antigen presentation, which impairs the immune response to
pulmonary pathogens.
THE ENDOCANNABINOID SYSTEM AND
THE LUNGS
Endocannabinoids are known to regulate immune cell functions,
either through cannabinoid receptors or through numerous
metabolites (Turcotte et al., 2015). As discussed in Section “The
Cannabinoid Receptors and the Lungs,” a growing body of
evidence indicates that the endocannabinoid system is present
in human lungs, with most cell types expressing cannabinoid
receptors. Moreover, many structural and immune cells have
the ability to synthesize endocannabinoids when exposed to
inflammatory stimuli. The impact that this can have on lung
homeostasis and disease is not fully understood, and this section
discusses the existing in cellulo and in vivo evidence.
Impact of Endocannabinoids on
Structural Cells
Although airway epithelial cells constitute an extremely large
contact surface and an important physical barrier, very few
studies have investigated the impact of endocannabinoids
on their functions, with reports often focusing on immune
cells. A recently published study demonstrates that the
endocannabinoid AEA increases permeability of the airway
epithelial cell line Calu-3 (Shang et al., 2016). Of note, this effect
was caused by arachidonic metabolites rather than cannabinoid
receptor activation. This underscores that airway epithelial cells
do not only respond to exogenous cannabinoids, but also have
the ability to metabolize endocannabinoids into various bioactive
lipid mediators that can modulate immune cell functions. In this
respect, Nomura et al. showed that 2-AG is an important source
of prostaglandins in the lungs of mice (Nomura et al., 2011).
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These findings underscore the importance of 2-AG as a source
of arachidonic acid in the lungs, which can also be metabolized
by human neutrophils and eosinophils into leukotriene B4
and C4, respectively (Chouinard et al., 2011; Larose et al.,
2014).
Impact on Immune Cells
Alveolar Macrophage Functions
To our knowledge, there is currently no evidence of the
regulation of human AM functions by endocannabinoids.
However, a limited number of studies investigated the impact of
2-AG and AEA on macrophage cell lines. In this regard, AEA,
but not 2-AG, was found to impair NO and cytokine production
in the J774 murine macrophage cell line (Chang et al., 2001).
The potentiating effect of 2-AG on NO production was likely
caused by its metabolites arachidonic acid and prostaglandin
E2, as both lipids mimicked this effect. Moreover, there is
evidence of J774 macrophages being capable of synthesizing
PGD2-G and PGE2-G, which are COX-2 metabolites of 2-AG
(Alhouayek et al., 2013). The exogenous addition of PGD2-G
to J774 cultures downregulated LPS-induced IL-1β production
by these cells, whereas the addition of PGE2-G or PGF2α-G
had the opposite effect. Finally, PGD2-G reduced LPS-induced
inflammation in vivo. These findings, in addition to a previous
report showing that PGE2-G stimulated calcium mobilization
in RAW267.4 cells (Nirodi et al., 2004), support that COX-2
metabolites of endocannabinoids regulate macrophage functions,
although more research is prompted in order to identify the
receptors that mediate these effects. Whether or not these
mechanisms translate to human AMs and to lung inflammation
also remains to be investigated.
Leukocyte Recruitment
Leukocyte recruitment to the lungs is a complex process that
involves a cellular response to a chemotactic gradient and
transmigration through the endothelium. The mechanisms of
leukocyte chemotaxis modulation by cannabinoids varies from
one cell type to another. Noteworthy, the endocannabinoid 2-
AG was shown to exert effects on the endothelium itself, thus
promoting Jurkat T cell adhesion and transmigration (Sarafian
et al., 2008). These findings should be confirmed using primary
human leukocytes in order to clarify the possible role of this
mechanism in inflammatory disease.
Despite the conflicting data regarding the expression of CB
receptors in neutrophils, the impact of various cannabinoids
on neutrophil chemotaxis has been investigated. In one report,
the pretreatment of human neutrophils with 2-AG or the CB2
agonist JWH0151 impaired their chemotactic response to the
1Chemical names: JWH015 = (2-Methyl-1-propyl-1H-indol-3-yl)-1-naphtha-
lenylmethanone, CP55,940 = (–)-Cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)
phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol, JWH133 = (6aR,10aR)-3-(1,
1-dimethylbutyl)-6a,7,10,10a-tetra-hydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran,
JZL184 = 4-[Bis(1,3-benzodioxol-5-yl)hydroxy-methyl]-1-piperidinecarbo-
xylic acid 4-nitrophenyl ester, SR144528 = 5-(4-chloro-3-methyl-phenyl)-1-
[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-
1H-pyrazole-3-carboxamide, WIN55,212-2 = [(3R)-2,3-dihydro-5-methyl-3-
(4-morpholinylmethyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenyl-
methanone, monomethanesulfonate.
formylated peptide fMLP (Kurihara et al., 2006). The impact of
2-AG was blocked by the CB2 antagonist SR144528. Another
study found that 2-AG and AEA do not induce neutrophil
migration in vitro (Chouinard et al., 2011). However, 2-AG can
stimulate other functions of human neutrophils, such as bioactive
lipid synthesis, antimicrobial peptide release and oxidative
burst (Chouinard et al., 2013). Importantly, these effects were
shown to be CB2-independent, underscoring the importance
of endocannabinoid metabolites in the regulation of neutrophil
functions.
Endocannabinoids have also been implicated in eosinophil
recruitment. Eosinophils are granulocytes that are found in
minimal numbers in the blood of healthy individuals, but
their levels are elevated in allergic diseases such as atopic
dermatitis and asthma, or in parasitic infections. Their
recruitment to the bronchial tissue and the airways is a hallmark
of asthma and they actively participate in the onset and
persistence of a chronic inflammatory state. As mentioned in
Section “The Cannabinoid Receptors and the Lungs,” human
eosinophils strongly express the CB2 receptor, making them
highly responsive to cannabinoids. In this respect, 2-AG was
found to be a chemoattractant for human primary eosinophils
in vitro (Oka et al., 2004; Kishimoto et al., 2006; Larose
et al., 2014). Noteworthy, the eosinophil differentiation factor
and priming agent IL-5 greatly potentiates the effect of 2-AG
(Larose et al., 2014). Furthermore, the CB2 receptor agonist
JWH133 primed the response of eosinophils toward other
chemoattractants (Frei et al., 2016). Although the principle
of 2-AG-induced migration of eosinophils was confirmed
in vivo in a murine model of dermatitis (Oka et al., 2006),
the important impact that this could have on eosinophil
migration to the lungs in asthmatic subjects remains to be
defined. Of note, there have been two distinct case reports of
individuals who developed an eosinophilic pneumonia following
marijuana consumption (Liebling and Siu, 2013; Natarajan
et al., 2013) suggesting that cannabinoids could promote and/or
induce an excessive recruitment of eosinophils to the lungs in
humans.
IMPACT OF CANNABINOIDS ON HOST
DEFENSE IN VIVO
Evidence from Animal Models
Given how cannabinoids can modulate immune cell functions
(as detailed in Section “Impact of Cannabinoids on Acute
Lung Inflammation”), it is likely that they have an impact
on host defense to various pathogens. In this respect, murine
models of lung infection were used to assess the involvement of
cannabinoids in immunity against viruses and bacteria. Table 1
summarizes the data obtained from animal models of pulmonary
infection. Noteworthy, the administration of cannabinoids in
these protocols was never in the form of cannabis smoking,
but rather as the direct administration of cannabinoids. These
studies all point to the conclusion that the administration
of plant-derived or synthetic cannabinoids impairs pathogen
clearance and in certain cases, increases mortality. Of note,
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TABLE 1 | Impact of cannabinoids on pulmonary host defense in mouse models and humans.
Treatment Dose (administration
route)
Model (species) Effects Reference
19-THC 25–75 mg/kg (oral
gavage)
Influenza A/PR/8/34
infection (mouse)
↑ Viral hemagglutinin 1 mRNA Buchweitz et al., 2007
↓ CD4+ and CD8+ cells in BALF
↓ Macrophages in BALF
75 mg/kg (oral gavage) ↓ IFN-γ-producing CD4+ cells Karmaus et al., 2013a
↓ IL-17-producing NK cells
↓ Antigen-presenting cells and
inflammatory myeloid cells
8 mg/kg (i.v.) Legionella pneumophila
infection (mouse)
↑ Mortality Klein et al., 1993; Smith et al.,
1997↑ Bacterial load in lungs
↑ Serum levels of acute-phase cytokines
Shift from Th1 to Th2 immunity Newton et al., 2009
CBN 16 mg/kg (i.v.) Legionella pneumophila
infection (mouse)
↑ Mortality Smith et al., 1997
↑ Bacterial load in lungs
CBD 8-16 mg/kg (i.v.) Legionella pneumophila
infection (mouse)
No significant effects on mortality or
bacterial load
Smith et al., 1997
CP55,940 6 mg/kg (i.v.) Legionella pneumophila
infection (mouse)
↑ Mortality Smith et al., 1997
↑ Bacterial load in lungs
CB1−/−CB2−/− n/a Influenza A/PR/8/34
infection (mouse)
↑ Pro-inflammatory mediator mRNA Karmaus et al., 2011
↑ T cell activation
↑ IL-17 and IFN-γ production by NK cells
and T cells
↑ APC maturation
BALF, bronchoalveolar lavage fluid; CBD, cannabidiol; CBN, cannabinol; NK, natural killer; APC, antigen presenting cells; i.v., intravenous.
one study used cannabinoid receptor-deficient mice in their
model of influenza infection, underscoring the involvement of
cannabinoid receptors in the detrimental effects of 19-THC on
lung immunity (Karmaus et al., 2011).
IMPACT OF CANNABINOIDS ON ACUTE
LUNG INFLAMMATION
Acute lung injury (ALI) is characterized by a disruption of
the vascular endothelium and the alveolar epithelium. There
are numerous causes for ALI, including sepsis, pneumonia,
aspiration of gastric contents, toxic gas inhalation, trauma and
blood transfusion. At the cellular level, ALI causes the loss
of alveolar–capillary membrane integrity, excessive neutrophil
transmigration, and the release of pro-inflammatory mediators
(Johnson and Matthay, 2010). Endotoxins such as LPS are
often used to induce acute lung inflammation in animals, as
this results in a pulmonary edema and neutrophilia mimicking
human ALI. The impact of endocannabinoids, cannabinoids
and even synthetic CB receptor agonists has been studied in
these animal models of ALI. Table 2 summarizes the effects of
cannabinoid treatment on the disease, which are, in most cases,
beneficial. One study found that cannabidiol treatment worsens
LPS-induced ALI (Karmaus et al., 2013b), contradicting previous
studies that showed the opposite (Table 2). However, the route of
administration of CBD was not consistent from one study to the
other (oral gavage vs. intraperitoneal), possibly accounting for the
different impact observed. Of note, a study by Costola-de-Souza
et al. (2013) used the monoacylglycerol lipase inhibitor JZL184 to
increase 2-AG levels in the lungs of ALI mice, which resulted in
an attenuation of ALI. Of note, CB1 and CB2 receptor antagonists
partially blocked the impact of JZL184, indicating that other
mechanisms are possibly involved in the effect of JZL184. Given
that JZL184 can prevent the 2-AG-induced LTB4 biosynthesis
by neutrophils as well as prostaglandin synthesis in the murine
lung (Chouinard et al., 2011; Nomura et al., 2011), it is possible
that the effect of JZL184 implicates not only the activation of
cannabinoid receptors but also a decrease in the synthesis of
several eicosanoids. Nevertheless, the positive impact that this
approach had on lung damage and inflammation underscores the
potential of such pathway modulation strategies in ALI therapy
development.
CONCLUSION AND PERSPECTIVES
Initial studies unraveled that cannabis smoking has deleterious
effects on lung function and inflammation, some of which are
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TABLE 2 | Impact of cannabinoids on pulmonary inflammation.
Treatment Dose (administration
route)
Model (species) Effects Reference
ANTI-INFLAMMATORY
19-THC 0.83 mg/kg (i.n.) LPS-induced lung inflammation (mouse) ↓ Neutrophils in BALF Berdyshev et al., 1998
↓ TNF-α
20 mg/kg (i.p.) Endotoxin B-induced lung inflammation
(mouse)
↓ Mortality Rao et al., 2015
↑ Airway resistance
↓ Vascular leak
↓ Leukocyte infiltration
↓ Pro-inflammatory cytokines
WIN55,212-
2
3.9 µg/kg (i.n.) LPS-induced lung inflammation (mouse) ↓ Neutrophils in BALF Berdyshev et al., 1998
↓ TNF-α
AEA 26.1 ng/kg (i.n.) LPS-induced lung inflammation (mouse) ↓ Neutrophils in BALF Berdyshev et al., 1998
↓ TNF-α
CBD 20-80 mg/kg (i.p.) LPS-induced lung inflammation (mouse) ↑ Lung function Ribeiro et al., 2012; Ribeiro
et al., 2015↓ Leukocyte recruitment
↓ Pro-inflammatory cytokines
↓ Myeloperoxidase
JWH133 1 mg/kg (i.p.) Neurogenic pulmonary edema (rat) ↓ Mortality Fujii et al., 2016
↓ Myeloperoxidase
5–20 mg/kg (i.p.) Paraquat-induced lung injury (rat) ↓ Pulmonary edema Liu et al., 2014
↓ Lung damage
↓ Neutrophil infiltration
JZL184 16 mg/kg (i.p.) LPS-induced acute lung injury (mouse) ↓ Leukocyte recruitment Costola-de-Souza et al., 2013
↓ Lung damage
↓ Pro-inflammatory cytokines
PRO-INFLAMMATORY
CBD 75 mg/kg (oral gavage) LPS-induced lung inflammation (mouse) ↑ Inflammatory cell infiltration Karmaus et al., 2013b
↑ LPS-induced pulmonary lesions
↑ TNF-α, IL-6, IL-23 and G-CSF mRNA
G-CSF, granulocyte-colony stimulating factor; i.n., intranasal; i.p., intraperitoneal.
not caused by tobacco smoking. Of note, cannabinoids are
involved in many of these effects. More recently, new tools
and animal models indicate that the downregulation of immune
cell functions by cannabinoids/endocananbinoids could dampen
pulmonary inflammation to such an extent that it could diminish
host defense. Thus, it becomes urgent to revisit the impact
of cannabis smoking, cannabinoids and endocananbinoids on
lung damages and pulmonary inflammation with more recent
molecular and pharmacological tools. In addition, it is unclear
to which extent the data obtained in animal models are
translatable to humans. In that regard, additional studies should
be undertaken to better decipher the impact of cannabis
smoking and/or administration on human lung integrity and
functions as well as to delineate if targeting endocannabinoids
might provide new or complementary benefits compared to
cannabinoids. Given that some of the anti-inflammatory effects
of endocannabinoids are mediated by their metabolites, the
modulation of endocannabinoid metabolic pathways might
prove itself a better alternative to increase the beneficial effects
of the cannabinoid system while limiting the detrimental ones.
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